eFFECTOR Therapeutics, Inc.

eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on translation control biology, developing medicines for oncology and other serious diseases. The company pursued a path to public markets through a merger with Locust Walk Acquisition Corp. (Nasdaq: LWAC), a blank-check company sponsored by Locust Walk Capital that completed its IPO in 2021. This 10-Q quarterly report, filed with the SEC on June 3, 2021, under accession number 0001193125-21-180751, was submitted during the pre-closing period of the SPAC transaction. The de-SPAC process ultimately brought eFFECTOR to Nasdaq under the ticker EFTR in the healthcare and biopharmaceuticals sector. Sign up at SpacDesk for full filing history, transaction timelines, and sponsor intelligence on this deal and hundreds more.